If the FDA follows an advisory committee’s vote, it can potentially be a transformative step in the delivery of mental health ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Acalabrutinib–Venetoclax improves progression-free survival and reduces disease progression in untreated chronic lymphocytic ...

FDA convened a joint meeting of its Drug Safety and Risk Management Advisory Committee and the Psychopharmacologic Drugs ...

Radium-223 re-treatment is safe for metastatic castration-resistant prostate cancer, per findings from the 2025 ASCO GU ...

With clozapine, other problems seem to be overshadowed by the possibility of neutropenia. These include serious conditions such as pneumonia, seizures, myocardiopathy, and constipation. Ileus is ...

Among 196 doctors who prescribed clozapine, 64% said the positive aspects of the REMS certification process outweighed the ...

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...

Patient safety and well-being is behind Rosemere Cancer Foundation’s New Year re-reprint of chemotherapy alert cards.

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.